Dr. Morris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-794-5446
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Duke University HospitalResidency, Internal Medicine, 2008 - 2011
University of Tennessee Health Science Center College of MedicineClass of 2008
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2012 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Start of enrollment: 2018 Mar 07
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Start of enrollment: 2019 Jun 14
Publications & Presentations
PubMed
- 1 citationsSoftware-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomise...Bruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, Brian M Anderson, Caleb S O'Connor
The Lancet. Gastroenterology & Hepatology. 2025-03-13 - Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer.Arjun S Peddireddy, Ryan Huey, Robert A Wolff, Kangyu Lin, Jocelyn Mitchell
Cancers. 2025-03-10 - A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.Jibran Ahmed, Anne Knisely, Carlos Torrado, Bettzy Stephen, Yali Yang
The Oncologist. 2025-03-10
Journal Articles
- Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-ChallengeB Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology
Lectures
- NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Are We Moving the Needle in Advanced Colorectal and Anal Cancers?ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Press Mentions
MD Anderson Unveils Key Research Breakthroughs: Highlights from March 12, 2025March 12th, 2025- MD Anderson Research Highlights for March 12, 2025March 12th, 2025
- Gastrointestinal Medical Oncologist and Researcher Driven to Help Patients Live LongerOctober 8th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
